Drug Approval | February 10, 2025
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
Subscribe To Our Newsletter & Stay Updated
